Key Highlights
- India’s Sun Pharmaceutical Industries has put forward a reported $13 billion all-cash acquisition proposal for Organon (OGN)
- If finalized, this transaction would represent Sun Pharma’s biggest acquisition in company history, backed by financing from JP Morgan, MUFG, and Citi
- Shares of OGN surged approximately 25% during Friday trading, building on a 20% year-to-date rally
- German pharmaceutical firm Grünenthal and private equity giant EQT have submitted rival acquisition proposals
- The latest bid follows Sun Pharma’s earlier $12 billion proposal submitted earlier this month
Shares of Organon (OGN) experienced a dramatic rally exceeding 25% during Friday’s trading session following breaking news that India’s Sun Pharmaceutical Industries has submitted a $13 billion all-cash takeover proposal for the women’s healthcare specialist.
The Economic Times broke the story Thursday evening, referencing sources with direct knowledge of the negotiations. OGN shares climbed approximately 8% during afterhours trading before continuing their upward trajectory throughout Friday’s regular market hours.
When the initial reports surfaced, Organon maintained a market capitalization of merely $2.2 billion. The proposed $13 billion acquisition would constitute an extraordinary premium relative to the company’s recent trading levels.
Should the transaction close, it would establish a new record as Sun Pharma’s most significant acquisition. The all-cash structure is reportedly supported by complete financing commitments from JP Morgan, MUFG, and Citi.
Sun Pharma intends to integrate Organon directly into its current business structure. The transaction would not involve issuing Sun Pharmaceutical equity to existing Organon shareholders.
This represents Sun Pharma’s second attempt to acquire the company. Reports from earlier in the month indicated the Indian pharmaceutical manufacturer submitted a $12 billion proposal. The newly reported $13 billion offer represents a $1 billion escalation within just weeks.
Competing Suitors Enter the Bidding War
Sun Pharma faces competition in its pursuit of Organon. Germany-based pharmaceutical company Grünenthal alongside Swedish private equity powerhouse EQT have both reportedly submitted competing acquisition proposals.
This competitive bidding environment underscores the strategic value of Organon’s product lineup — an extensive collection of medications and therapies concentrated primarily on women’s healthcare, complemented by its valuable U.S. manufacturing capabilities.
Organon emerged as an independent entity following its separation from Merck in June 2021. Subsequently, the stock has experienced significant volatility, declining nearly 30% over the trailing twelve months despite Friday’s substantial upward movement.
Massive Surge in Trading Activity
The acquisition speculation catalyzed significant trading interest. Approximately 5.2 million OGN shares traded hands in the initial hours following Friday’s market open — approaching its entire three-month average daily volume of 5.9 million shares in merely the opening period.
Friday’s impressive 25.47% appreciation elevated the stock’s year-to-date performance to a positive 20.25% gain.
OGN traded above the $9.20 per share threshold during Thursday’s afterhours session, representing a substantial increase from its comparatively modest $2.2 billion market capitalization at Thursday’s closing bell.
Neither Sun Pharma nor Organon has issued official statements confirming any agreement as of Friday afternoon.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
